Previous 10 | Next 10 |
So far in 2022, Regeneron Pharmaceuticals (NASDAQ: REGN) stock has fallen by 14%. It recently hit a new 52-week low and trades at an incredibly low earnings multiple. But the company won't be able to rely on revenue from its COVID-19 treatment to prop up its financials anymore, and ...
Regeneron Pharmaceuticals, Inc. (REGN) Goldman Sachs 43rd Annual Global Healthcare Conference Transcript June 14, 2022, 11:40 AM ET Executives Bob Landry - Chief Financial Officer Marion McCourt - Head, Commercial Ryan Crowe - Investor Relations Analysts Salveen Richter - Goldman Sachs Presen...
A single injection of Adverum Biotechnologies' (NASDAQ:ADVM) ADVM-022 for wet AMD demonstrated therapeutic aflibercept expression levels over three years and was well tolerated. Results also showed that ADVM-022 led to a massive reduction in the need for supplemental anti-VEGF injections. ADV...
Alnylam Pharmaceuticals (NASDAQ:ALNY), a biotech focused on RNA interference, announced Thursday that its experimental RNAi therapy cemdisiran caused a 37% mean reduction of an important indicator of disease progression in immunoglobulin A nephropathy ((IgAN)). Alnylam (ALNY) has partnered wi...
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi (NASDAQ:SNY) on Tuesday said the U.S. FDA had approved their medicine Dupixent for children aged 6 months to 5 years with inflammation of the skin. The indication is specifically for children aged 6 months to 5 years with moderate-to-severe a...
FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis PR Newswire Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, experienced significan...
3 Top Biotech Stocks For Your June 2022 Watchlist For investors looking for the most active stocks in the stock market now, biotech stocks could be a go-to. After all, companies across the industry are constantly providing key updates on their latest developmental pipeline advan...
Regeneron Pharmaceuticals (NASDAQ: REGN) had a day to forget, at least as far as its stock was concerned. The company's shares took a more than 4% hit after the company announced a pricey deal in the oncology space. Regeneron announced that it's buying out its partner Sanofi ...
Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer PR Newswire Regeneron will secure global rights to Libtayo fr...
Kuros Biosciences (OTCPK:CSBTF) said $2.5M of a $5M milestone payment due to Kuros will be paid to Xoma (NASDAQ:XOMA), as Checkmate Pharmaceuticals' acquisition was completed by Regeneron Pharmaceuticals. In July 2021, Xoma acquired a royalty interest position Kuros held, under a 20...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...